4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases
Status:
Completed
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
The current Rethinking Clinical Trials (REaCT) trial will compare two schedules(12- vs.
4-weekly) of bone-targeting agents (BTAs) to evaluate quality of life, pain and skeletal
events within the Canadian Health Care System. This study will use an "integrated consent
model" that involves "oral consent" rather than a written informed consent writing process as
the study is comparing standard schedules and not a new administration schedule.